MedTrace Logo

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2025-08-05

No results posted yet for this study

Summary

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Conditions

  • Lung Cancer Diagnosis

Interventions

DIAGNOSTIC_TEST

blood draw

Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.

Sponsors & Collaborators

  • Freenome Holdings Inc.

    lead INDUSTRY

Principal Investigators

  • Victoria Sumner · Freenome Holdings Inc.

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2026-06-15
Completion
2027-06-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122077 on ClinicalTrials.gov